A "cocktail" combination of two monoclonal antibodies respectively acting on
different
sites of the platelet GPIIb-IIIa complex has been disclosed. This "cocktail" combination
can completely block receptor function of the GPIIb-IIIa complex, inhibit platelet
aggregation and thereby efficiently inhibit thrombosis.